350 related articles for article (PubMed ID: 26771811)
41. Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias.
Rocquain J; Carbuccia N; Trouplin V; Raynaud S; Murati A; Nezri M; Tadrist Z; Olschwang S; Vey N; Birnbaum D; Gelsi-Boyer V; Mozziconacci MJ
BMC Cancer; 2010 Aug; 10():401. PubMed ID: 20678218
[TBL] [Abstract][Full Text] [Related]
42. Age-related mutations and chronic myelomonocytic leukemia.
Mason CC; Khorashad JS; Tantravahi SK; Kelley TW; Zabriskie MS; Yan D; Pomicter AD; Reynolds KR; Eiring AM; Kronenberg Z; Sherman RL; Tyner JW; Dalley BK; Dao KH; Yandell M; Druker BJ; Gotlib J; O'Hare T; Deininger MW
Leukemia; 2016 Apr; 30(4):906-13. PubMed ID: 26648538
[TBL] [Abstract][Full Text] [Related]
43. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.
Gelsi-Boyer V; Trouplin V; Roquain J; Adélaïde J; Carbuccia N; Esterni B; Finetti P; Murati A; Arnoulet C; Zerazhi H; Fezoui H; Tadrist Z; Nezri M; Chaffanet M; Mozziconacci MJ; Vey N; Birnbaum D
Br J Haematol; 2010 Nov; 151(4):365-75. PubMed ID: 20880116
[TBL] [Abstract][Full Text] [Related]
44. Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia.
Ouyang Y; Qiao C; Chen Y; Zhang SJ
Oncotarget; 2017 Mar; 8(13):20834-20841. PubMed ID: 28209919
[TBL] [Abstract][Full Text] [Related]
45. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
46. Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia.
Yamazaki J; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Shen L; Kantarjian HM; Estecio MR; Jelinek J; Godley LA; Issa JP
Epigenetics; 2012 Feb; 7(2):201-7. PubMed ID: 22395470
[TBL] [Abstract][Full Text] [Related]
47. TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.
Pérez C; Martínez-Calle N; Martín-Subero JI; Segura V; Delabesse E; Fernandez-Mercado M; Garate L; Alvarez S; Rifon J; Varea S; Boultwood J; Wainscoat JS; Cruz Cigudosa J; Calasanz MJ; Cross NC; Prósper F; Agirre X
PLoS One; 2012; 7(2):e31605. PubMed ID: 22328940
[TBL] [Abstract][Full Text] [Related]
48. Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.
Kanagal-Shamanna R; Luthra R; Yin CC; Patel KP; Takahashi K; Lu X; Lee J; Zhao C; Stingo F; Zuo Z; Routbort MJ; Singh RR; Fox P; Ravandi F; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE
Oncotarget; 2016 Mar; 7(12):14251-8. PubMed ID: 26883102
[TBL] [Abstract][Full Text] [Related]
49. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
50. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
[TBL] [Abstract][Full Text] [Related]
51. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
Abdel-Wahab O; Manshouri T; Patel J; Harris K; Yao J; Hedvat C; Heguy A; Bueso-Ramos C; Kantarjian H; Levine RL; Verstovsek S
Cancer Res; 2010 Jan; 70(2):447-52. PubMed ID: 20068184
[TBL] [Abstract][Full Text] [Related]
52. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Tefferi A
Leukemia; 2010 Jun; 24(6):1128-38. PubMed ID: 20428194
[TBL] [Abstract][Full Text] [Related]
53. Chronic myelomonocytic leukemia: 2016 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2016 Jun; 91(6):631-42. PubMed ID: 27185207
[TBL] [Abstract][Full Text] [Related]
54. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia.
Kar SA; Jankowska A; Makishima H; Visconte V; Jerez A; Sugimoto Y; Muramatsu H; Traina F; Afable M; Guinta K; Tiu RV; Przychodzen B; Sakaguchi H; Kojima S; Sekeres MA; List AF; McDevitt MA; Maciejewski JP
Haematologica; 2013 Jan; 98(1):107-13. PubMed ID: 22773603
[TBL] [Abstract][Full Text] [Related]
55. TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Tezcanlı Kaymaz B; Cömert Özkan M; Aktan Ç; Küçükaslan AŞ; Şahin F; Kosova B; Saydam G
Turk J Haematol; 2017 Jun; 34(2):174-178. PubMed ID: 28218607
[TBL] [Abstract][Full Text] [Related]
56. Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis.
Traina F; Visconte V; Jankowska AM; Makishima H; O'Keefe CL; Elson P; Han Y; Hsieh FH; Sekeres MA; Mali RS; Kalaycio M; Lichtin AE; Advani AS; Duong HK; Copelan E; Kapur R; Olalla Saad ST; Maciejewski JP; Tiu RV
PLoS One; 2012; 7(8):e43090. PubMed ID: 22905207
[TBL] [Abstract][Full Text] [Related]
57. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
58. Genomic determinants of chronic myelomonocytic leukemia.
Patel BJ; Przychodzen B; Thota S; Radivoyevitch T; Visconte V; Kuzmanovic T; Clemente M; Hirsch C; Morawski A; Souaid R; Saygin C; Nazha A; Demarest B; LaFramboise T; Sakaguchi H; Kojima S; Carraway HE; Ogawa S; Makishima H; Sekeres MA; Maciejewski JP
Leukemia; 2017 Dec; 31(12):2815-2823. PubMed ID: 28555081
[TBL] [Abstract][Full Text] [Related]
59. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor-Binding Sites in Chronic Myelomonocytic Leukemia.
Yamazaki J; Jelinek J; Lu Y; Cesaroni M; Madzo J; Neumann F; He R; Taby R; Vasanthakumar A; Macrae T; Ostler KR; Kantarjian HM; Liang S; Estecio MR; Godley LA; Issa JP
Cancer Res; 2015 Jul; 75(14):2833-43. PubMed ID: 25972343
[TBL] [Abstract][Full Text] [Related]
60. Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
Duchmann M; Yalniz FF; Sanna A; Sallman D; Coombs CC; Renneville A; Kosmider O; Braun T; Platzbecker U; Willems L; Adès L; Fontenay M; Rampal R; Padron E; Droin N; Preudhomme C; Santini V; Patnaik MM; Fenaux P; Solary E; Itzykson R
EBioMedicine; 2018 May; 31():174-181. PubMed ID: 29728305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]